TrialPloS one2017

Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients.

Mikael Ebbo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.